Cardiovascular Risks | Boehringer Ingelheim

Skip to main content

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Home
Therapeutic Areas
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our focus articulates who we are and what we strive for, how we work and what we want to achieve.

Therapeutic Areas

Metabolic

Cardiovascular

Respiratory
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact us
Logout

Boehringer Ingelheim

Leave this field blank

Efficacy

Twynsta Website Banner Update

Cardiovascular Risks

Hypertension is often Associated with other CV Risks

Document ID: PC-ZA-102731 | Expiry Date: 17/07/2026

Efficacy

Telmisartan's Positive Impact on Proteinuria

Synergistic Benefits of Telmisartan and Amlodipine

Cardiovascular Risks

RELATED CONTENT

Telmisartan 's Positive Effect on Proteinuria

PDF

Telmisartan 's Positive Effect on Proteinuria

PC-ZA-102734 (July 2026 )

Download Opens in new tab

Synergistic Effect of Telmisartan & Amlodipine

PDF

Synergistic Effect of Telmisartan & Amlodipine

PC-ZA-102732 (July 2026 )

Download Opens in new tab

Home
Cardiovascular
Twynsta
Cardiovascular Risks

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical Studies

Contact

Prescribing Information

Sitemap
Privacy
Terms of use

BI

.

To report any adverse events, please use the following email address: pv_local_south_africa@boehringer-ingelheim.com

© 2010-2023 Boehringer Ingelheim International GmbH. All rights reserved. PC-ZA-102790